Key Highlights

  • Shares closed at $1.37 at last closing, up 1.48%.
  • Waldencast has finalized the sale of its Obagi Medical Business to refocus on Milk Makeup and repay debt.
  • Milk Makeup's sales have reportedly declined significantly, prompting a turnaround plan and a strategic review.
  • The company has also delayed an Earnings release amid the transition.

Penny stock Waldencast (NASDAQ:WALD) is a beauty and wellness company that has centered its portfolio on the Milk Makeup cosmetics brand, having agreed to divest its Obagi Medical skincare business. Shares closed at $1.37 at last closing, up 1.48%.

The company has been navigating significant challenges, including declining sales at Milk Makeup, a strategic review, and delayed financial reporting, which makes it a turnaround situation rather than simply an overlooked stock.

Latest Developments

Waldencast has finalized the sale of its Obagi Medical business to refocus on Milk Makeup and to repay debt, but Milk Makeup's sales have reportedly declined significantly, prompting a turnaround plan, and the company has undertaken a strategic review and delayed an earnings release. Investors should verify the latest Revenue and its trends, margins, the status of the Obagi sale and Debt repayment, the details of any strategic review, and cash and debt levels directly from SEC filings.

Financial and Business Position

Waldencast's financial position is being reshaped by the divestiture of Obagi Medical, which provides proceeds to repay debt, leaving a company more concentrated in the Milk Makeup brand, whose sales have been declining. Investors should watch Milk Makeup's sales and their trajectory, gross and operating margins, the use of Obagi-sale proceeds and debt levels, cash, and the outcome of the strategic review.

Stock-Market Context

WALD shares closed at $1.37 at last closing, up 1.48%. The stock is a small-cap beauty company whose shares have been pressured by declining sales, the strategic review, and delayed reporting, and it remains volatile and sensitive to news about the turnaround.

What Investors Should Watch

Watch Milk Makeup's sales and their trajectory, gross and operating margins, the completion and use of proceeds from the Obagi sale, debt levels and cash, and the outcome and implications of the strategic review. Evidence that Milk Makeup's sales are stabilizing and that the Balance Sheet is strengthening would be needed to support the shares, while continued sales declines would be the principal risk.